The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...
Jules Hunt, DG Technology, Digital and Data - Ming Tang, CDIO (interim) / Chief Data and Analytics Officer - Ayub Bhayat, Director of Data Services / Deputy CDAO - David Ashby, Director of Clinical an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results